Comments
Glossary
Exit
Back
Next
Immunization: You Call the Shots
skip to end of menu by clicking now Influenza
 
 Objectives
 About Influenza
 About Influenza Vaccine
 Indications for Vaccination
 Contraindications and Precautions to Vaccination
 Use of the VIS
 Vaccine Storage and Handling
 Vaccine Administration
 Adverse Reactions Following Vaccination
 Resources

 

About Influenza Vaccine

For the 201819 influenza season, there are three types of influenza vaccine available in the United States inactivated influenza vaccine, recombinant influenza vaccine, or live attenuated influenza vaccine. Click on each type to learn more.

Inactivated Influenza Vaccines (IIVs) Recombinant Influenza Vaccine (RIV)
Live Attenuated Influenza Vaccine (LAIV)

Live attenuated influenza vaccine (LAIV)

LAIV was approved for use in the United States in 2003. It is given by the intranasal route. All live attenuated influenza vaccine is quadrivalent (LAIV4) and contains the same four influenza viruses as IIV4. The live attenuated influenza viruses in LAIV4 are temperature-sensitive. This means that they are cold-adapted, so they effectively replicate in the mucosa of the nasopharynx, but are less able to replicate in warmer body areas such as the lungs. LAIV4 is grown in chicken eggs. Each dose contains residual amounts of egg protein and gentamicin sulfate, but it does not contain thimerosal.

During the 201617 and 201718 influenza seasons, the Advisory Committee on Immunization Practices (ACIP) recommended that LAIV not be used because of concerns about low effectiveness against influenza A(H1N1)pdm09-like viruses circulating in the United States during the 201314 and 201516 seasons. On February 21, 2018, ACIP recommended that LAIV be an option for influenza vaccination of persons for whom it is appropriate for the 201819 season.

Learning Opportunity
Click here to learn more
about influenza vaccines.